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E xpression  of the  p latelet-derived grow th factor «-re­
cep to r (PDGFaR) gene is tigh tly  controlled in  m am m a­
lian  em bryo genesis. A well established  model system to 
study  hum an  em bryogenesis is the  em bryonal carci­
nom a cell line Tera2. We have shown previously th a t 
re tino ic  acid-d ifferen tiated  Tera2 cells express two 
PDGFarR tran sc rip ts  of 6.4 kilobase pairs  (kb) (encoding 
the  full-length recep tor) and  3.0 kb, respectively, 
w hereas in  contrast, und iffe ren tia ted  Tera2 cells ex­
press PDFGaR tran sc rip ts  of 1.5 kb and  5.0 kb. Here we 
show  th a t th is  sw itch in  PD G FaR expression p a tte rn  
d u rin g  d ifferen tia tion  of Tera2 cells resu lts from  a lte r­
na tive  p rom oter use. In  und ifferen tia ted  cells, a  second 
p rom oter is used, w hich is located in  in tron  12 of the 
PD G FaR gene. F unctional analysis shows th a t th is p ro ­
m oter contains a consensus octam er motif, w hich can be 
bound  by th e  POU dom ain tran sc rip tio n  factor Oct-4. 
Oct-4 is expressed in  und iffe ren tia ted  Tera2 cells b u t 
no t in  re tino ic  acid-induced d ifferen tia ted  cells. M uta­
tion  of th e  octam er m otif decreases prom oter activity, 
w hile ectopic expression of Oct-4 in  d ifferentiated  Tera2 
cells specifically enhances the  activ ity  of th is PDGFaR 
prom oter. Therefore, we suggest th a t an  im portan t as­
pect in  th e  m ain tenance of th e  und ifferen tia ted  sta te  of 
hum an  em bryonal carcinom a cells resu lts from  Oct-4 
expression, w hich th ereu p o n  activates th is PDGFaR 
prom oter.
P la te le t-d eriv ed  g row th  factor (PD G F)1 and  its  receptors 
p lay  a  p ro m in en t role d u rin g  early  m am m alian  development. 
A lready  in  th e  p re im p lan ta tio n  em bryo of th e  m ouse, from the 
two-cell s tag e  onw ards to  th e  b lastocyst stage, th e  PDGF-A 
chain  is expressed  (1), w hile  bo th  th is  gene and  th e  cognate 
PD G F  a-recep to r (PD G FaR ) gene a re  expressed in early  
p o s tim p lan ta tio n  em bryos (2). M u rine  em bryonal carcinom a 
(EC) cells in  cu ltu re  sec re te  PDGF-AA (3) and  express the  
P D G F aR  following d iffe ren tia tion  by retinoic  acid (4), The im ­
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portance of the  PD G FaR  in  m am m alian  developm ent is also 
exemplified by the  Patch (Ph) m ouse m u ta n t. The P h  m u ta n t  
lacks p a r t  of the PD G F aR  gene (5, 6) and  d isp lays severe 
developm ental defects in m esoderm al a n d  neuroectoderm al t is ­
sues, often resu ltin g  in  p ren a ta l le th a lity  (7, 8).
An im portan t model system  for s tudy ing  h u m a n  early  em ­
bryogenesis is th a t  of te s ticu la r  germ  cell tum ors. T hese  tu m o rs  
are derived from a  deran g em en t of a p rim ord ial germ  cell in  
early  life, which f irs t develops into a noninvasive carcinoma-ira 
situ  and  subsequently  grow out as a sem inom a or a nonsem i- 
nom atous tum or (9). The stem  cells o f nonsem inom atous tu ­
mors, also referred  to as EC  cells, strongly  resem ble  cells of th e  
early  p re im plan ta tion  h u m a n  embryo. V arious es tab lish ed  h u ­
m an  EC cell lines, am ong o thers the  T era2  cell line, can  be 
induced to d ifferentia te  in vitro into a v a r ie ty  of m a tu re , non- 
tum origenic cell types by th e  m orphogen retinoic ac id  (10). W e 
have recently  show n th a t  d ifferen tia tion  of T era2  EC  cells by 
retinoic acid (RA) is accom panied by a  sh ift in expression  of 
PD G FaR  mRNA v a ria n ts  ( l l ) . 2 F ou r h u m a n  P D G F aR  t r a n ­
scripts have been identified  as a  re su lt  of a  com bination  of 
a lte rna tive  splicing and  prom oter use. Two P D G F aR  m RN A  
species of 1.5 and  5.0 kb, respectively, a re  expressed  in early  
h u m an  embryonic cells, including the  u n d iffe ren tia ted  T era2  
EC cells. S tudies on surgically  rem oved te s tic u la r  germ  cell 
tum ors have shown th a t  th e  1.5-kb P D G F aR  tra n sc r ip t  can  be 
used  as a selective m a rk e r  for carcinom a-i/i situ ,  sem inom a, 
and  undifferen tia ted  nonsem inom atous tum ors in  th e  h u m a n  
tes tis .2 In  d ifferen tia ted  cells, includ ing  R A -differen tia ted  
Tera2 (Tera2 RA) cells, two o ther P D G F aR  tra n sc r ip ts  of 6.4 
kb, which encodes th e  functional fu ll-leng th  recep tor, and  of
3.0-kb, w hich poten tia lly  encodes a  dom inan t n eg a tiv e  isoform, 
have been identified. A b e rra n t expression o f th e  fu ll-leng th  
PD G FaR  receptor, encoded by th e  6.4~kb tra n sc r ip t,  h a s  also 
been im plicated in tum origenesis, i.e. i t  is overexpressed  in  
various tum ors, including gliom as (12).
In  a previous s tu dy  we cloned and  charac te rized  th e  h u m a n  
PD G FaR  gene prom oter (P I), which gives rise  to th e  6.4- an d
3.0-kb transcrip ts . A ctivity  of th is  P I  p rom oter can  be s t im u ­
la ted  strongly by RA an d  cAMP (13). S im ilar s tu d ie s  w ith  
respect to the  m ouse and  r a t  P D G F aR  p rom oter h av e  been  
published recently  (14,15). In th e  p re sen t s tudy  we have  cloned 
and  characterized  th e  second P D G F aR  gene p ro m o ter (P2), 
w hich gives rise to th e  1.5- and  5.0-kb tra n sc r ip ts  in  ea rly  
embryonic cells. We show here th a t  the P 2  prom oter, located in  
in tron  12 of the PD G F aR  gene, is active in  u n d iffe ren tia ted  
T era2  cells and  is controlled by the  P O U  dom ain tra n sc r ip tio n  
factor Oct-4. Oct-4 expression is detected  in  T era2  EC  cells b u t  
not in  Tera2 RA cells.
2 Mosselman, S., Looijenga, L. H. J., Gillis, A. J. M., van Rooijen, M. 
A., Kraft, H. J., Van Zoelen, E. J. J., and Oosterhuis, J. W. (1996) Proc. 
Natl. Acad. ScL U. S. A. 93, 2884-2888.
12873
12874 Oct-4 Regulates PDGFaR Promoter in Human EC Cells
MATERIALS AND METHODS
Cell Culture — Tcra2 clone 13 (Tera2) cells were grown in a-modifi- 
cation of minimal essential medium lacking nucleosides and de- 
oxynucleosides, supplemented with 10% (v/v) fetal calf serum and 44 
mM NaHCOa in a 7.5% C 02 atmosphere at 37 °C. Differentiation of cells 
was induced by the addition of RA (5 /¿M) 16 h after the cells were 
seeded at low density {5.0 x 10:* cells/cm2) and maintained at this 
medium for 7 days, prior to further analysis or transfection.
PDGFaR P2 Promoter Constructs — Nucleotide sequence analysis 
was performed using the Pharmacia T7 sequencing kit. PDGFaR P2 
promoter constructs were generated by standard cloning procedures 
(16), using either restriction fragments or DNA fragments obtained by 
the polymerase chain reaction. Mutation of the octamer binding site 
was performed with the Altered Sites system kit (Promega), according 
to the manufacturer’s protocol. All fragments were inserted in the 
multiple cloning site of the pSLA4 luciferase reporter plasmid (13).
Transfection} Luciferase, and fi-Galactosidase Assays—Promoter- 
luciferase constructs were transiently transfected into either undiffer­
entiated (Tera2 EC) or differentiated (Tera2 RA) cells using the calcium 
phosphate coprecipitation method (16). Luciferase activity was deter­
mined 48 h (Tera2 EC) or 72 h  (Tera2 RA) post-transfection (Luciferase 
assay kit, Promega). The luciferase activity was corrected for transfec­
tion efficiency by measuring the j3-galactosidase activity of a lacZ gene 
driven by an SV40-promoter of a cotransfected pCHHO plasmid (17). 
Every experiment was done in duplicate and repeated at least twice 
with two batches of DNA.
RNA Analysis—Total RNA was isolated from undifferentiated (EC) 
or differentiated (7 days of RA treatment) Tera2 cells, using the iso- 
thiocyanate method (18). After poly(A)+ isolation, the mRNA was quan­
titated spectrophotometrically and subjected to 1% agarose gel electro­
phoresis in form amide. The amount and integrity of loaded mRNA was 
controlled by ethidium bromide staining, after which it was transferred 
to Hybond-N (Amersham Corp.). Hybridization and washing proce­
dures were carried out as described (11). A mouse Oct-4 cDNA probe 
(kindly provided by Dr. P. C. van der Vliet, University of Utrecht), was 
labeled by random priming (19) using a labeling kit (Amersham).
Electrophoretic Mobility Shift Assay (EMSA)—DNA restriction frag­
ments were filled in by Klenow polymerase treatment in the presence of 
[a-32P]dCTP. Oligonucleotides for EMSAs were end-labeled using 
[7-32P]ATP and T4 polynucleotide kinase. Double-stranded oligonucleo­
tides were separated from single-stranded oligonucleotides by poly­
acrylamide gel electrophoresis. The oct-lc consensus oligonucleotide 
was purchased from Promega. Nuclear extracts were prepared as de­
scribed (20). Binding reactions and gel electrophoresis were performed 
essentially as described (21). The mouse anti-Oct-4-antibody has been 
described by Rosfjord and Rizzino (22).
RESULTS
Sequence Determination and Characterization of the P2 Pro­
moter of the PDGFaR Gene—Two alternative PDGFaR tran­
scripts, of 1.5 and 5.0 kb, respectively, are specifically ex­
pressed in the undifferentiated Tera2 embryonal carcinoma 
cells. Although, the transcripts terminate differently as a result 
of alternative splicing, both transcripts initiate in intron 12 of 
the PDGFaR gene ( l l ).2 In order to functionally characterize 
this putative promoter, which was designated P2 promoter, the 
region was cloned and sequenced (Fig. 1). The sequence up­
stream from the transcription initiation site lacks a TATA box, 
which is also the case for the PDGFaR PI promoter in human 
(13), mouse (14), and rat (15), and is also not extremely GC- 
rich. In the promoter region, several consensus binding sites for 
transcription factors could be detected, including API, AP2, 
and PE A3 motifs (23). A consensus octamer binding site is 
located in the transcribed region, at positions +28 to + 35.
We first set out to determine the functional relevance of 
these putative binding sites and of other regions required for 
activity of the PDGFaR promoter. It is of interest to note that 
the P2 promoter region is demethylated in both undifferenti­
ated and RA-induced differentiated Ter a 2 cells.3 A series of 
progressive deletion mutants of the PDGFaR P2 promoter was
3 H. J. Kraft, unpublished results.
-842 t cgagtaatag tagtaatagt agaataggtt tccgtacagc
-801 tggctctgtg tgtaattaaa ccctttttct attgcaattc ccctgtcttg
-751 gtaaatcggc tctgtctagg cggacaagga gaatccatcg ggcggttata
PEA3
-701 agagctgccc cccaatttca aatatttata tctaagcttt ctttattttc
-651 ctgcctattt cccaacaagg gatgaggagc ttagggagtt aaaaagtagt
-601 aaaatatgga ggaaaagggc ataattccca ttataccaag aggcattgct
-551 ggtgaaggca atacctttcc aggtacgatt ttcagtaaca cagacgtgcg
PEA3
-501 agtaagaggc agtgttggct gttagtgtct tttatgagcc aqtcttttcc
-451 tggcttgcta tccgtggtga gactgacacc caaatgttct ctcagagtct
-401 ctttcagggt ggaacaaaca ggcttcaggg tctttacgta tgtctcctcc
-351 caacatgaag 
PE A3
ctaattgctg tgctctcggg catgtttagc tcttggtaga
-301 atcroctttcc
API
taacaaatag ggagcagtgg aggccagcct gaagttLtta
-251 tttaatcact acttagaatc gatgatattt tgaatactga agtatttcca
-201 gtggctagta atttactaag acaaaagatg cccctgtttg catatggaaa
-151 acagaagggg
AP2
agagagccag gaggtgtggg tgagagcccc gaaggcaaga
-101 qqatcccaqa qqctggccca gcacggagct ggtaagacac ggcgcctcac
-51 acccagggag ggctgcaccc tcctttctcc cgtctgtgtt
OCT
ttctttccct
1 TGCAAGTGTT ATTCGACAAA AGCAATTATG CTAATTTCCT
PEA3
TCCfGTGGGC
51 TCAATTCCTT t t t t t g a c a c GATGACTTAG GAGGAGTCAT TATGATTGCT








Fig. 1. The nucleotide sequence  o f the  PD G FaR  gene P 2 p ro ­
m oter and  5 ' -un transla ted  reg io n  o f the  1.5-kb tra n sc r ip t .  The
transcription initiation site (11) is numbered nucleotide 1, and the 
transcribed region is given in uppercase letters. The sequence is given 
up to exon 13, Indicated in the figure are the consensus binding sites for 
transcription factors API, AP2, and PE A3, which are underlined, and 
for a POU domain transcription factor, which is depicted in boldface. 
Note the absence of a TATA box in the promoter, (GenBank™/EMBL 
data base accession number X95095).
cloned in front of a luciferase reporter gene, transiently trans­
fected into undifferentiated Tera2 cells, and assayed for pro­
moter activity (Fig. 2). The luciferase activity of the complete 
intron 12 promoter sequence of approximately 2.5 kb (clone 
—2500/+182) was comparable with that of the much smaller 
clone -668/+182, indicating that no important expression in­
formation is pertained upstream from nucleotide - 668, up to 
exon 12 of the PDGFaR gene. A further deletion, down to 
position -102  (clone -102/+182), displayed only fractionally 
lower activity than the clones -2500/+182 and -668/+182, 
which further limits the region necessary for control of high 
level expression. The reverse orientation of the —668/+182 
fragment in the pSLA4 vector (clone -668/+182R) almost com­
pletely abolished activity, demonstrating the orientation de­
pendence of the P2 promoter. These data show that intron 12 of 
the PDGFaR gene contains a bona fide promoter.
Deletion mutants generated at the 3' end (clones; -668/+14; 
- 102/ + 14), which still included an intact transcription initia­
tion site, reduced activity 4-5 times, compared with the paren­
tal clones -668/+182 and -102/+182. Thus, a cis-element 
determining high promoter activity is located in the tran­
scribed part, within the region +14 to +182. The consensus 
octamer motif ATGCTAAT at position +28 to +35, which is 
present in all the constructs that show high promoter activity, 
was thereupon mutated to the sequence ACGCCAAT (clones 
-668/+182M and -102/+182M, respectively). This mutation






Clone Activity (± SD)
— — ------ -------------------------------  -  » -2 5 0 0 /+ IS 2  92 ±11
---------------------------------►---------668/+182 100 ±28
----------------------------------- X_______ *________-66B/+182M 30 ±8
a ------------------------------------------------ -668/+182R 5 ±2
--------------------------- ->  -668/+14 3 8 ± 3
----------------------------------IÖ2/+182 80 ±3
------------------- X_______ ► -102/+I82M 20 ±1
--------------- ► -1 0 2 /+ M  22 ±4
Fig. 2. A ctiv ity  of PD G FaR  gene P 2 p ro m o te r m u tan ts  in  T era 2 EC cells is dependent on an  octam er motif. A series of 5' or 3' deletion 
mutants or of octamer motif point mutants was cloned in front of a luciferase reporter gene and transiently transfected into Tera2 EC ceils. Exons 
(Ex) and restriction sites (By Bamïll\ H> HiriDïll\ T, Taql) are depicted in the figure. Luciferase activity was assayed 48 h post-transfection. 
Transfection efficiency was normalized for with /3-galactosidase activity of a cotransfected pCHHO plasmid (Pharmacia Biotech Inc.). Values are 
presented as mean promoter activity relative to the clone -668/+182, which was arbitrarily set at 100% (S.D. is indicated).
is expected to abrogate all fortuitous binding of POU domain- 
specific proteins (24, 25). Upon changing these two nucleotides 
in the octamer motif, promoter activity drops by a factor of 3- 4, 
comparable with deletion of the complete +14/+182 region 
(Fig. 2). This indicates that the octamer motif is indeed in­
volved in directing P2 promoter activity in Tera2 EC cells,
In order to demonstrate that Tera2 EC nuclear proteins can 
actually bind to the octamer motif, an EMSA was performed. It 
is shown in Fig. 3A that the intact —102/+182 promoter frag­
ment forms a complex with nuclear extracts of Tera2 EC cells. 
The formation of this complex can be specifically competed by 
excess (100 times) unlabeled probe itself, but not by the - 102/ 
+ 182M fragment containing the mutated octamer motif (lane 
4). Moreover, the -102/+182M fragment does not form a com­
plex in this EMSA (Fig. 3A, lanes 5-8). In addition, the - 102/ 
+182 fragment competed efficiently the four specific complexes 
of a consensus oct-lc oligonucleotide (Promega) with nuclear 
extracts of EC cells, while the “ 102/+182M fragment was 
refractory to competition (Fig. SB).
In conclusion, an octamer motif is involved in the regulation 
of the P2 promoter of the PDGFaR gene in undifferentiated 
human embryonal carcinoma cells.
Oct-4 Binds to the PDGFaR P2 Promoter Octamer Mo­
tif— As described previously, the major change in constitu­
ents of octamer binding proteins during retinoic acid-induced 
differentiation of murine embryonal carcinoma cells involves 
the down-regulation of Oct-4 expression (26). We hence hy­
pothesized that also in the undifferentiated human embryo-* 
nal carcinoma Tera2 cells the POU domain transcription 
factor Oct-4 is present and occupies the promoter P2 octamer 
motif, oct-P.
In order to test this hypothesis a series of EMSAs were 
performed with a double-stranded oligonucleotide (oct-P), 
which results in a higher resolution compared with the long 
promoter fragment. The oct-P contains the octamer sequence 
and flanking 7 nucleotides at the 3' side and 8 nucleotides at 
the 5' side of the P2 promoter (+20/+42). The resulting com­
plexes were compared with the complexes formed by the con­
sensus oct-lc oligonucleotide (see above). The oct-P as well as 
the oct-lc oligonucleotide gave rise to the formation of several 
complexes with nuclear proteins of Tera2 EC cells, Tera2 RA 
cells, or mouse F9 EC cells, which could be specifically com­
peted by excess of the respective cold probe itself (Fig. 4; see 
also Fig. 5). In the EMSAs, oct-lc and oct-P displayed identical 
bandshift patterns (not shown). Based upon the complexes 
formed with the nuclear extracts of mouse F9 EC cells (27, 28) 
a positive identification of the Oct-4 complex with Tera2 EC or
RA extracts was made possible, and is indicated in Fig. 4A. 
This shows that also during RA-induced differentiation of hu­
man Tera2 embryonal carcinoma cells the POU domain tran­
scription factor Oct-4 is down-regulated,
To confirm the results obtained with the above described 
EMSAs, a Northern blot analysis was performed on mRNA of 
Tera2 EC and Tera2 RA cells. The blot was probed with a 
labeled Oct-4 cDNA, which showed that Oct-4 mRNA is present 
in Tera2 EC cells, contrasting with the absence of any detect­
able Oct-4 mRNA in Tera2 RA cells (Fig. 4B). Conclusive evi­
dence that the indicated Oct-4 complex in the EMSAs is formed 
with this transcription factor comes from a supershift analysis. 
This analysis was performed with an anti-Oct4-antibody (22), 
which only supershifted the Oct-4-containing complex and not 
the Oct-1 complex (Fig. 4C).
Hence, undifferentiated human Tera2 embryonal carcinoma 
cells express Oct-4, which can complex with the P2-octamer 
motif. The cells cease to express Oct-4 upon RA-induced differ­
entiation, which necessarily excludes complex formation be­
tween Oct-4 and the oct-P motif.
Comparison of the oct-P Binding Site with the Consensus 
oct-lc Motif—The members of the POU transcription factor 
family are defined by their ability to bind to the octamer motif. 
This causes experimental pitfalls to distinguish between the 
binding of the different members to a particular motif in a 
specific cell type (29). In addition to the octamer consensus 
motif, however, the nucleotides juxtaposed to the motif are also 
important to the affinity and specificity of binding of a given 
Oct protein (24).4 Therefore, we set out to compare the binding 
properties of the consensus oct-lc and the PDGFaR gene- 
derived oct-P motifs with nuclear extracts from Tera2 EC cells 
in EMSAs. The oct-P-derived complexes could not be competed 
by a 500-fold excess of the consensus oct-lc oligonucleotide, 
while competition with oct-P itself was easily established. A 
100-fold excess of oct-P competitor was sufficient for strong 
competition. No signal was detectable with a 500-fold excess of 
competitor, even upon prolonged exposure (Fig. 5). This indi­
cates that the oct-P oligonucleotide is bound stronger by POU 
proteins from Tera2 cells than the consensus oct-lc oligonu­
cleotide. The results with the oct-P oligonucleotide are con­
firmed by the reciprocal experiment, using the oct-lc oligonu­
cleotide as probe. Even with 100-fold excess, the oct-P 
competitor abolished the specific binding to the oct-lc oligonu­
cleotide, while the oct-lc oligonucleotide was needed in larger
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12878 Oct-4 Regulates PDGFaR Promoter in Human EC Cells
of the octamer flanking sequences of kFGF, REX-1, and 
PDGFaR shows, however, that the motifs cannot be aligned 
adequately to explain the preferential binding of Oct-4 to these 
sites. Accessory proteins might therefore explain Oct-4-depend- 
ent regulation (see above).
The role of proteins encoded by these alternative PDGFaR 
transcripts, if any, remains obscure, since presently none of 
these proteins have been detected in vivo. The sequence of the
5.0-kb messenger suggests a putative oncogene-like action, 
which may be important for autonomous growth of Tera2 EC 
cells. Undifferentiated Tera2 cells have been shown to prolif­
erate in the absence of serum growth factors (34). A possible 
role in development or differentiation may also be inferred from 
the expression patterns of alternative PDGFaR transcripts. 
P2~initiated transcripts have been identified in human oocytes 
and preimplantation stages5 and in human testis tumors.2 The 
down-regulation of the 1.5-kb transcript expression in spermat­
ogenesis suggests that the P2-promoter is active in cells of the 
female primordial germ cell lineage, probably in the commit­
ment of cells during embryonal development. Alternative tran­
scripts, generated by differential promoter use and/or splicing, 
of other tyrosine kinase receptors have been described, includ­
ing the genes for PDGF/3R (4), FGF receptors (35), epidermal 
growth factor receptor (36), c-kit (37) and PDGFaR of the 
mouse (38). Interestingly, an alternative transcript of approx­
imately 4.8 kb of the PDGFaR gene has been detected in the 
mouse embryonal carcinoma cell line F9, but only after RA- 
induced differentiation (38). This transcript has also been de­
scribed by Lee et al. (39) and is regulated in a differentiation- 
specific manner. Any conclusive evidence concerning functions 
of the corresponding alternative proteins remains lacking, 
however.
In conclusion, the POU transcription factor Oct-4 controls 
the developmentally regulated expression by the PDGFaR P2 
promoter. Whether the down-regulation of Oct-4 during RA- 
induced differentiation is a prerequisite for the activation of 
the PDGFaR promoter PI remains to be determined. We are 
currently working toward this goal.
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